Patients who received an implantable heart rhythm monitor after suffering a heart attack did not have fewer subsequent cardiovascular events overall, but a subset of patients whose heart attack was classified as non-ST segment elevation myocardial infarction (NSTEMI) did see strong benefits, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.
Although the trial did not meet its primary endpoint, the results suggest that monitoring for abnormal heart rhythms could help guide care for patients with NSTEMI heart attacks, according to researchers. NSTEMI heart attacks result from a gradual stiffening of the artery, which constrains the flow of blood to the heart. Patients who suffer NSTEMI heart attacks are generally older, have more risk factors and have more advanced heart disease than those who suffer STEMI heart attacks, which occur when a blood clot suddenly blocks an artery to the heart, depriving the heart of oxygen completely. The findings suggest that early identification of arrythmias may be more clinically useful following NSTEMI heart attacks.
"In NSTEMI patients, we found that diagnosing an investigated asymptomatic arrhythmia with an implantable cardiac monitor prevented cardiac events, whereas it didn't in STEMI patients," said Christian Jøns, MD, an electrophysiologist at Rigshospitalet in Copenhagen, Denmark and the study's lead author. "Even though the main study was negative, our sub-analysis indicates that NSTEMI patients could benefit from continuous [heart rhythm] monitoring and intervention."
Having an abnormal heart rhythm, or arrhythmia, is not always dangerous on its own, but it can increase the risk of cardiovascular problems and may be an early marker of more serious problems, such as worsening heart failure or a blood vessel that is becoming too narrow. Previous studies have shown that a large proportion of heart attack survivors develop arrhythmias before suffering subsequent cardiac events. The trial sought to assess whether identifying those arrhythmias early could help doctors intervene and prevent subsequent events.
The trial's primary endpoint was a composite of cardiovascular death or acute unscheduled hospitalization for heart failure, arrhythmia, acute coronary syndrome, stroke, major bleeding or systemic embolism. The analysis revealed a trend toward reduced primary endpoints among patients who received an implantable cardiac monitor, but the difference was not statistically significant.
A prespecified sub-analysis revealed that NSTEMI patients were about 30% less likely to experience the primary composite endpoint if they received an implantable cardiac monitor.The researchers also noted that a greater proportion of patients who received the cardiac monitor had their therapy adjusted to account for arrhythmias. This suggests the monitors were useful in alerting doctors to heart rhythm problems such as atrial fibrillation, which can be asymptomatic and commonly go undiagnosed, Jøns said.
The trial was stopped earlier than anticipated because of an unexpectedly high rate of non-cardiovascular events detected among patients who received an implantable cardiac monitor at the time of the first interim analysis. Enrollment was paused while researchers and the sponsor worked to reduce this bias. The issue was eventually resolved.
In addition to implantable cardiac monitors, some newer wearable devices such as smartwatches are being investigated as potential tools for detecting asymptomatic arrhythmias. Jøns said that even though the optimal method for heart rhythm monitoring and the optimal target population remains to be defined, there is good evidence that monitoring heart rhythm and treating any arrhythmia improves overall outcomes in selected high-risk patients after a heart attack.